Novartis Scoops up EU rights to Pfizer's Remicade Biosimilar, Targets Merck

Fierce Biotech reported that Novartis has expanded its reach in Europe, buying the continental rights to a Pfizer-developed take on the blockbuster Remicade.
According to the news:

Through its Sandoz business, Novartis is paying an undisclosed sum for the European rights to PF-06438179, an autoimmune treatment now in Phase III development. As a condition of its $17 billion acquisition of Hospira last year, Pfizer promised EU antitrust authorities that it would exit the European market for Remicade biosimilars while it presses forward in the U.S. with a similar product invented by partner Celltrion.

Click here to view the full article.